DOCSLIB.ORG

Adenosine Receptor Agonists Deepen the Inhibition of Platelet Aggregation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adenosine Receptor Agonists Deepen the Inhibition of Platelet Aggregation Vascular Pharmacology 113 (2019) 47–56 Contents lists available at ScienceDirect Vascular Pharmacology journal homepage: www.elsevier.com/locate/vph Adenosine receptor agonists deepen the inhibition of platelet aggregation by T P2Y12 antagonists ⁎ Magdalena Boncler ,1, Joanna Wzorek1, Nina Wolska, Dawid Polak, Cezary Watala, Marcin Rozalski Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland ARTICLE INFO ABSTRACT Keywords: Several adenosine receptor (AR) agonists have been shown in the past to possess anti-platelet potential; however, Platelet the adjunctive role of AR agonists in anti-platelet therapy with the use of P2Y12 receptor inhibitors has not been Adenosine receptor elucidated so far. P2Y12 antagonist This in vitro aggregation-based study investigates whether the inhibition of platelet function mediated by Dual anti-platelet therapy cangrelor or prasugrel metabolite can be potentiated by AR agonists. It evaluates the effect of non-selective (2- Aggregation chloroadenosine), A2A-selective (UK 432097, MRE 0094, PSB 0777) and A2B-selective AR agonists (BAY 60- 6583) on platelet function in relation to their toxicity, specificity towards adenosine receptor subtypes, structure and solubility. UK 432097, 2-chloroadenosine, MRE 0094 and PSB 0777 were found to be more or less potent inhibitors of ADP-induced platelet aggregation when acting alone, and that they remained non-cytotoxic to the cells. These AR agonists were also effective in the potentiation of the effects exerted12 byP2Y antagonists. Considering the estimated IC50 value, UK 432097, showing a relatively high binding affinity to the2A A adenosine receptor, has been identified as the most potent anti-aggregatory agent. This compound diminished platelet aggregation at nanomolar concentrations and further augmented platelet inhibition by P2Y12 antagonists by approx. 60% (P < .01). Our results indicate the importance of adenosine receptors as therapeutic targets and point out challenges and potential benefits of therapeutic use of a combined therapy12 ofP2Y antagonist and AR agonist in cardiopro- tection. Our comparative analysis of the effects of AR agonists on platelet response in plasma and whole blood may indirectly suggest that other blood morphology elements contribute little to the inhibition of platelet function by AR agonists. 1. Introduction or use combined therapy based on currently-available agents. Adenosine diphosphate (ADP) is a crucial mediator of both phy- Activation of blood platelets plays a crucial role in the initiation and siological haemostasis and thrombosis. Although ADP is regarded as a development of arterial thrombotic diseases, which are the leading weak agonist of blood platelets, it is nonetheless an important factor cause of morbidity and mortality in Western countries. Therefore, an- promoting platelet activation induced by other activators (thrombin, tiplatelet therapy is the ‘first choice’ in the management and treatment collagen); these activators themselves promote ADP release from in- of arterial thrombotic disorders [1]. Despite the fact that many anti- traplatelet storage pools, such as dense granules, where it is present in platelet agents are currently available and some are widely applied as molar concentrations. It results in a positive feedback that enhances drugs, the clinical problem of the effective treatment of arterial platelet aggregation and platelet plug formation. Additionally, ADP acts thrombosis has not been fully solved [2–4]. Therefore, there is still a synergistically to other platelet agonists, even the weak ones, such as need to develop novel platelet inhibitors with better efficacy and safety serotonin, adrenaline or chemokines [5]. ⁎ Corresponding author at: Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, ul. Mazowiecka 6/8, 92-215 Lodz, Poland. E-mail address: [email protected] (M. Boncler). 1 Both authors contributed equally to this manuscript. https://doi.org/10.1016/j.vph.2018.11.005 Received 24 July 2018; Received in revised form 1 October 2018; Accepted 18 November 2018 Available online 22 November 2018 1537-1891/ © 2018 Elsevier Inc. All rights reserved. M. Boncler et al. Vascular Pharmacology 113 (2019) 47–56 Platelets express two receptors for ADP: the P2Y1 receptor, which 2. Materials and methods initiates platelet aggregation, and the P2Y12 receptor, which enhances this process, leading to thrombus formation. P2Y12 has become a more 2.1. Chemicals attractive therapeutic target than P2Y1 for preventing arterial throm- botic disorders [6]. The major clinically approved P2Y12 inhibitors in- Adenosine receptor agonists were purchased from Tocris Bioscience clude the thienopyridines (ticlopidine, clopidogrel and prasugrel), the (Bristol, UK) (BAY 60-6583, PSB 0777 and 2-chloroadenosine), Toronto ATP analogue cangrelor and the cyclopentyl-triazolo-pyrimidine Research Chemicals (Toronto, Canada) (MRE 0094) or Axon Medchem (CPTP) derivative-ticagrelor [3,6]. Thienopyridines are prodrugs that (Reston, VA, USA) (UK 432097). Cangrelor (AR-C69931MX) was from are converted to short-living active metabolites that irreversibly in- Cayman Chemical (Ann Arbor, MI, USA). Prasugrel metabolite (R- activate the receptor and consequently inhibit ADP-induced platelet 138727) was obtained from BOC Sciences (Shirley, NY, USA). Calcein activation. Cangrelor is the first intravenous 12P2Y receptor inhibitor, AM was obtained from Molecular Probes (Eugene, OR, USA). which reversibly blocks ADP signaling in a non-competitive manner. Monoclonal antibodies anti-human CD61/PerCP, CD62/PE, PAC-1/ Ticagrelor is an allosteric antagonist of P2Y12, acting directly via re- FITC, mouse IgG1/PE isotype control, mouse IgG1/FITC isotype con- versible binding to the P2Y12 receptor, resulting in the non-competitive trol, Cellfix, buffered sodium citrate was obtained from Becton- inhibition of ADP-induced P2Y12 activation; it is therefore used in the Dickinson (San Diego, CA, USA). Phosphate buffered saline (PBS) was prevention of thromboembolic events in patients with acute coronary obtained from Biomed Lublin (Lublin, Poland). Dimethyl sulfoxide syndromes [3,6,7]. Clopidogrel, prasugrel, and ticagrelor are the most (DMSO), adenosine diphosphate (ADP) were obtained from Sigma (St. frequently-used oral platelet P2Y12 inhibitors in current clinical prac- Louis, MO, USA). All other chemicals, unless otherwise stated, were tice. Although all three agents have indications for use in acute cor- purchased from POCH (Gliwice, Poland). onary syndromes, current guidelines favour prasugrel and ticagrelor over clopidogrel because of their superior clinical benefits [8]. In turn, 2.2. Subjects cangrelor, being the first intravenously-administered 12P2Y inhibitor to be approved, seems to be the most promising option for percutaneous Human blood was obtained from healthy donors, who gave their coronary interventions [9]. written informed consent (35 men and 65 women; mean age Adenosine serves not only as a component of nucleic acids and the 29 ± 10 years). All individuals confirmed not having taken medica- most important energy carrier in the cell (ATP), but also as a signaling tions known to influence platelet function (e. g. non-steroidal anti-in- molecule which regulates tissue function [10,11]. Adenosine receptors flammatory drugs, NSAIDs) for at least two weeks prior to the study. (AR) are a subfamily of G-protein-coupled receptors, found in mem- The study was approved by the Human Studies Committee of the branes of various human cells and playing various physiological func- Medical University of Lodz (Poland) and was conducted in accordance tions. Of four known adenosine receptor subtypes (A1,A2A,A2B and with the guidelines established by the Declaration of Helsinki. A3), platelets express only A2A and A2B. Of the platelet AR receptors, A2A is regarded as a high affinity receptor, and platelets have a sig- 2.3. Collection and processing of blood samples nificantly higher density2A ofA than A2B [10,12,13]. Agonization of platelet AR results in an enhanced intracellular cAMP level and con- Whole blood was collected into the polypropylene tubes with a sequently leads to the inhibition of platelet activation and aggregation blood to citrate ratio of 9:1 (vol:vol). Platelet-rich plasma (PRP) was [11,14]. Therefore, the adenosine receptors A2A and A2B could act as prepared by 12-min of 190 ×g centrifugation of a withdrawn blood at targets for antiplatelet therapy, especially under circumstances when 37 °C. Platelet-poor plasma (PPP) was obtained by centrifuging PRP classical therapy of antagonizing the other purinergic receptor P2Y12 is samples at 2000 x g for 15 min at 37 °C. Platelets in plasma were insufficient or problematic. Apart from the natural agonist, adenosine, counted using photometry [38] and their count was adjusted to 8 a group of synthetic, longer-lasting agonists of A2A and A2B receptors 2 × 10 cells/ml. To ensure that the washing procedure did not arte- also exists [11–13,15]. This group includes agonists with good se- factually activate the platelets, the expression of P-selectin and active lectivity for A2A or A2B receptors, as well as non-selective compounds form of GPIIbIIIa in PRP was randomly monitored with the use of flow that activate more than one type of adenosine receptor. Several A2A cytometry (CD62P/PE-positive and PAC-1/FITC objects within CD61/ and A2B agonists have been tested clinically, and two
Load more

Recommended publications
  • Lysophosphatidic Acid and Its Receptors: Pharmacology and Therapeutic Potential in Atherosclerosis and Vascular Disease
    JPT-107404; No of Pages 13 Pharmacology & Therapeutics xxx (2019) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease Ying Zhou a, Peter J. Little a,b, Hang T. Ta a,c, Suowen Xu d, Danielle Kamato a,b,⁎ a School of Pharmacy, University of Queensland, Pharmacy Australia Centre of Excellence, Woolloongabba, QLD 4102, Australia b Department of Pharmacy, Xinhua College of Sun Yat-sen University, Tianhe District, Guangzhou 510520, China c Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, St Lucia, QLD 4072, Australia d Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA article info abstract Available online xxxx Lysophosphatidic acid (LPA) is a collective name for a set of bioactive lipid species. Via six widely distributed G protein-coupled receptors (GPCRs), LPA elicits a plethora of biological responses, contributing to inflammation, Keywords: thrombosis and atherosclerosis. There have recently been considerable advances in GPCR signaling especially Lysophosphatidic acid recognition of the extended role for GPCR transactivation of tyrosine and serine/threonine kinase growth factor G-protein coupled receptors receptors. This review covers LPA signaling pathways in the light of new information. The use of transgenic and Atherosclerosis gene knockout animals, gene manipulated cells, pharmacological LPA receptor agonists and antagonists have Gproteins fi β-arrestins provided many insights into the biological signi cance of LPA and individual LPA receptors in the progression Transactivation of atherosclerosis and vascular diseases.
    [Show full text]
  • SYNTHESIS and BIOLOGICAL Actnnry of CONFORMATIONALLY CONSTRAINED WLEOSIDES and NUCLEOTIDES
    SYNTHESIS AND BIOLOGICAL ACTnnrY OF CONFORMATIONALLY CONSTRAINED WLEOSIDES AND NUCLEOTIDES A thesis submitted in conformity with the requirements for the degree of Masters of Science Graduate Department of Chemistry University of Toronto National Library Bibliothèque nationaie B*m ofCanada du Canada Acquisitions and Acquisitions et Bibliographie Setvices services bibliographiques 395 Wellington Street 395. rue Wellington ûttawaON K1AW OctawaON KlAW canada canada The author has granted a non- L'auteur a accorde une licence non exclusive Licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distn'buer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/fïlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. Spthesis and Biologicai Activity of Conformationaliy Constrained NucIeosides and Nuc1eotides Degree of Master of Science, 1998 by Girolamo Tusa Graduate Department of Chemistry, University of Toronto This thesis outhes the synthesis of a variety of confonnationally constrained nucleosides and nucleotide analogues. The conformationally 'locked" analogues closely resemble specific conformers of natural nucleosides and nucieotides and were used to probe the conformationai specificity of particular physiological processes in PC 12 ce&; nucleoside transport (NT) activity and Pt-purinoceptor response.
    [Show full text]
  • Extracellular Adenosine Triphosphate and Adenosine in Cancer
    Oncogene (2010) 29, 5346–5358 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW Extracellular adenosine triphosphate and adenosine in cancer J Stagg and MJ Smyth Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Adenosine triphosphate (ATP) is actively released in the mulated the hypothesis of purinergic neurotransmission extracellular environment in response to tissue damage (Burnstock, 1972). Burnstock’s hypothesis that ATP and cellular stress. Through the activation of P2X and could be released by cells to perform intercellular P2Y receptors, extracellular ATP enhances tissue repair, signaling was initially met with skepticism, as it seemed promotes the recruitment of immune phagocytes and unlikely that a molecule that acts as an intracellular dendritic cells, and acts as a co-activator of NLR family, source of energy would also function as an extracellular pyrin domain-containing 3 (NLRP3) inflammasomes. messenger. Nevertheless, Burnstock pursued his work The conversion of extracellular ATP to adenosine, in and, together with Che Su and John Bevan, reported contrast, essentially through the enzymatic activity of the that ATP was also released from sympathetic nerves ecto-nucleotidases CD39 and CD73, acts as a negative- during stimulation (Su et al., 1971). Three decades later, feedback mechanism to prevent excessive immune responses. following the cloning and characterization of ATP and Here we review the effects of extracellular ATP and adenosine adenosine cell surface receptors, purinergic signaling is a on tumorigenesis. First, we summarize the functions of well-established concept and constitutes an expanding extracellular ATP and adenosine in the context of tumor field of research in health and disease, including cancer immunity.
    [Show full text]
  • Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CH
    Chronotropic, Dromotropic and Inotropic Effects of Dilazep in the Intact Dog Heart and Isolated Atrial Preparation Shigetoshi CHIBA, M.D., Miyoharu KOBAYASHI, M.D., Masahiro SHIMOTORI,M.D., Yasuyuki FURUKAWA, M.D., and Kimiaki SAEGUSA, M.D. SUMMARY When dilazep was administered intravenously to the anesthe- tized donor dog, mean systemic blood pressure was dose depend- ently decreased. At a dose of 0.1mg/Kg i.v., the mean blood pressure was not changed but a slight decrease in heart rate was usually observed in the donor dog. At the same time, a slight but significant decrease in atrial rate and developed tension of the iso- lated atrium was induced. Within a dose range of 0.3 to 1mg/Kg i.v., dilazep caused a dose related decrease in mean blood pressure, bradycardia in the donor dog, and negative chronotropic, dromo- tropic and inotropic effects in the isolated atrium. At larger doses of 3 and 10mg/Kg i.v., dilazep caused marked hypotension, fre- quently with severe sinus bradycardia or sinus arrest, especially in isolated atria. When dilazep was infused intraarterially at a rate of 0.2-1 ƒÊ g/min into the cannulated sinus node artery of the isolated atrium, negative chrono- and inotropic effects were dose dependently in- duced. With respect to dromotropism, SA conduction time (SACT) was prolonged at infusion rates of 0.2 and 0.4ƒÊg/min. But at 1ƒÊg, dilazep caused an increase or decrease of SACT, indicating a shift of the SA nodal pacemaker. It is concluded that dilazep has direct negative chrono-, dromo- and inotropic properties on the heart at doses which produced no significant hypotension.
    [Show full text]
  • P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases
    International Journal of Molecular Sciences Review P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases Derek Strassheim 1, Alexander Verin 2, Robert Batori 2 , Hala Nijmeh 3, Nana Burns 1, Anita Kovacs-Kasa 2, Nagavedi S. Umapathy 4, Janavi Kotamarthi 5, Yash S. Gokhale 5, Vijaya Karoor 1, Kurt R. Stenmark 1,3 and Evgenia Gerasimovskaya 1,3,* 1 The Department of Medicine Cardiovascular and Pulmonary Research Laboratory, University of Colorado Denver, Aurora, CO 80045, USA; [email protected] (D.S.); [email protected] (N.B.); [email protected] (V.K.); [email protected] (K.R.S.) 2 Vascular Biology Center, Augusta University, Augusta, GA 30912, USA; [email protected] (A.V.); [email protected] (R.B.); [email protected] (A.K.-K.) 3 The Department of Pediatrics, Division of Critical Care Medicine, University of Colorado Denver, Aurora, CO 80045, USA; [email protected] 4 Center for Blood Disorders, Augusta University, Augusta, GA 30912, USA; [email protected] 5 The Department of BioMedical Engineering, University of Wisconsin, Madison, WI 53706, USA; [email protected] (J.K.); [email protected] (Y.S.G.) * Correspondence: [email protected]; Tel.: +1-303-724-5614 Received: 25 August 2020; Accepted: 15 September 2020; Published: 18 September 2020 Abstract: Purinergic G-protein-coupled receptors are ancient and the most abundant group of G-protein-coupled receptors (GPCRs). The wide distribution of purinergic receptors in the cardiovascular system, together with the expression of multiple receptor subtypes in endothelial cells (ECs) and other vascular cells demonstrates the physiological importance of the purinergic signaling system in the regulation of the cardiovascular system.
    [Show full text]
  • NIH Public Access Author Manuscript Neuron Glia Biol
    NIH Public Access Author Manuscript Neuron Glia Biol. Author manuscript; available in PMC 2006 May 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuron Glia Biol. 2006 May ; 2(2): 125±138. Purinergic receptors activating rapid intracellular Ca2+ increases in microglia Alan R. Light1, Ying Wu2, Ronald W. Hughen1, and Peter B. Guthrie3 1 Department of Anesthesiology, University of Utah, Salt Lake City, UT, USA 2 Oral Biology Program, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27510, USA 3 Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142 Msc 7850, Bethesda, MD 20892-7850, USA Abstract We provide both molecular and pharmacological evidence that the metabotropic, purinergic, P2Y6, P2Y12 and P2Y13 receptors and the ionotropic P2X4 receptor contribute strongly to the rapid calcium response caused by ATP and its analogues in mouse microglia. Real-time PCR demonstrates that the most prevalent P2 receptor in microglia is P2Y6 followed, in order, by P2X4, P2Y12, and P2X7 = P2Y13. Only very small quantities of mRNA for P2Y1, P2Y2, P2Y4, P2Y14, P2X3 and P2X5 were found. Dose-response curves of the rapid calcium response gave a potency order of: 2MeSADP>ADP=UDP=IDP=UTP>ATP>BzATP, whereas A2P4 had little effect. Pertussis toxin partially blocked responses to 2MeSADP, ADP and UDP. The P2X4 antagonist suramin, but not PPADS, significantly blocked responses to ATP. These data indicate that P2Y6, P2Y12, P2Y13 and P2X receptors mediate much of the rapid calcium responses and shape changes in microglia to low concentrations of ATP, presumably at least partly because ATP is rapidly hydrolyzed to ADP.
    [Show full text]
  • Use of Uridine in Combination with Choline for the Treatment Of
    (19) TZZ ¥ _T (11) EP 2 329 829 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/7072 (2006.01) A61K 31/14 (2006.01) 16.04.2014 Bulletin 2014/16 A61K 31/685 (2006.01) A61P 25/28 (2006.01) (21) Application number: 10075661.8 (22) Date of filing: 30.07.1999 (54) Use of uridine in combination with choline for the treatment of neurological disorders Verwendung von Uridin in Kombination mit Cholin zur Behandlung neurologischer Erkrankungen Utilisation de l’uridine en combinaison avec la choline pour le traitement des maladies neurologiques (84) Designated Contracting States: • CACABELOSR ET AL: "THERAPEUTIC EFFECTS AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU OF CDP-CHOLINE IN ALZHEIMER’S DISEASE MC NL PT SE COGNITION, BRAIN MAPPING, CEREBROVASCULAR HEMODYNAMICS, AND (30) Priority: 31.07.1998 US 95002 P IMMUNE FACTORS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK (43) Date of publication of application: ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 08.06.2011 Bulletin 2011/23 January 1996 (1996-01-01), pages 399-403, XP008065562, ISSN: 0077-8923 (62) Document number(s) of the earlier application(s) in • SPIERS P A ET AL: "CITICOLINE IMPROVES accordance with Art. 76 EPC: VERBAL MEMORY IN AGING", ARCHIVES OF 09173495.4 / 2 145 627 NEUROLOGY, AMERICAN MEDICAL 07116909.8 / 1 870 103 ASSOCIATION, CHICAGO, IL, US, vol. 53, no. 5, 99937631.2 / 1 140 104 1 May 1996 (1996-05-01), pages 441-448, XP008028412, ISSN: 0003-9942 (73) Proprietor: Massachusetts Institute of Technology • WEISS G B: "Metabolism and actions of CDP- Cambridge, Massachusetts 02142-1601 (US) choline as an endogenous compound and administered exogenously as citicoline.", LIFE (72) Inventors: SCIENCES 1995 LNKD- PUBMED:7869846, vol.
    [Show full text]
  • Long-Term Oral Administration of Dipyridamole Improves Both
    913 Hypertens Res Vol.30 (2007) No.10 p.913-919 Original Article Long-Term Oral Administration of Dipyridamole Improves Both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-Randomized Study Shoji SANADA1),2), Hiroshi ASANUMA3), Yukihiro KORETSUNE4), Kouki WATANABE5), Shinsuke NANTO6), Nobuhisa AWATA7), Noritake HOKI2), Masatake FUKUNAMI2), Masafumi KITAKAZE3), and Masatsugu HORI1) Adenosine is known as an endogenous cardioprotectant. We previously reported that plasma adenosine lev- els increase in patients with chronic heart failure (CHF), and that a treatment that further elevates plasma adenosine levels may improve the pathophysiology of CHF. Therefore, we performed a prospective, open- randomized clinical trial to determine whether or not exposure to dipyridamole for 1 year improves CHF pathophysiology compared with conventional treatments. The study enrolled 28 patients (mean±SEM: 66±4 years of age) attending specialized CHF outpatient clinics with New York Heart Association (NYHA) class II or III, no major complications, and stable CHF status during the most recent 6 months under fixed medica- tions. They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in addition to their original medications and were followed up for 1 year. The other drugs were not altered. Among the enrolled patients, 100%, 4%, 100%, and 79% received angiotensin-converting enzyme inhibitors, aldosterone analogue, loop diuretics, and β-adrenoceptor blocker, respectively. Fifteen patients suffered from dilated cardiomyopathy, and 7/3/3 patients suffered from ischemic/valvular/hyperten- sive heart diseases, respectively. Mean blood pressure was comparable among the groups.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Blood Platelet Adenosine Receptors As Potential Targets for Anti-Platelet Therapy
    International Journal of Molecular Sciences Review Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy Nina Wolska and Marcin Rozalski * Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Science, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-504-836-536 Received: 30 September 2019; Accepted: 1 November 2019; Published: 3 November 2019 Abstract: Adenosine receptors are a subfamily of highly-conserved G-protein coupled receptors. They are found in the membranes of various human cells and play many physiological functions. Blood platelets express two (A2A and A2B) of the four known adenosine receptor subtypes (A1,A2A, A2B, and A3). Agonization of these receptors results in an enhanced intracellular cAMP and the inhibition of platelet activation and aggregation. Therefore, adenosine receptors A2A and A2B could be targets for anti-platelet therapy, especially under circumstances when classic therapy based on antagonizing the purinergic receptor P2Y12 is insufficient or problematic. Apart from adenosine, there is a group of synthetic, selective, longer-lasting agonists of A2A and A2B receptors reported in the literature. This group includes agonists with good selectivity for A2A or A2B receptors, as well as non-selective compounds that activate more than one type of adenosine receptor. Chemically, most A2A and A2B adenosine receptor agonists are adenosine analogues, with either adenine or ribose substituted by single or multiple foreign substituents. However, a group of non-adenosine derivative agonists has also been described. This review aims to systematically describe known agonists of A2A and A2B receptors and review the available literature data on their effects on platelet function.
    [Show full text]
  • The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies
    International Journal of Molecular Sciences Article The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies Aleksandra Szopa 1,* , Karolina Bogatko 1, Mariola Herbet 2 , Anna Serefko 1 , Marta Ostrowska 2 , Sylwia Wo´sko 1, Katarzyna Swi´ ˛ader 3, Bernadeta Szewczyk 4, Aleksandra Wla´z 5, Piotr Skałecki 6, Andrzej Wróbel 7 , Sławomir Mandziuk 8, Aleksandra Pochodyła 3, Anna Kudela 2, Jarosław Dudka 2, Maria Radziwo ´n-Zaleska 9, Piotr Wla´z 10 and Ewa Poleszak 1,* 1 Chair and Department of Applied and Social Pharmacy, Laboratory of Preclinical Testing, Medical University of Lublin, 1 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (K.B.); [email protected] (A.S.); [email protected] (S.W.) 2 Chair and Department of Toxicology, Medical University of Lublin, 8 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (M.H.); [email protected] (M.O.); [email protected] (A.K.) [email protected] (J.D.) 3 Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 1 Chod´zkiStreet, PL 20–093 Lublin, Poland; [email protected] (K.S.);´ [email protected] (A.P.) 4 Department of Neurobiology, Polish Academy of Sciences, Maj Institute of Pharmacology, 12 Sm˛etnaStreet, PL 31–343 Kraków, Poland; [email protected] 5 Department of Pathophysiology, Medical University of Lublin, 8 Jaczewskiego Street, PL 20–090 Lublin, Poland; [email protected] Citation: Szopa, A.; Bogatko, K.; 6 Department of Commodity Science and Processing of Raw Animal Materials, University of Life Sciences, Herbet, M.; Serefko, A.; Ostrowska, 13 Akademicka Street, PL 20–950 Lublin, Poland; [email protected] M.; Wo´sko,S.; Swi´ ˛ader, K.; Szewczyk, 7 Second Department of Gynecology, 8 Jaczewskiego Street, PL 20–090 Lublin, Poland; B.; Wla´z,A.; Skałecki, P.; et al.
    [Show full text]
  • Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines
    [CANCER RESEARCH 61, 7217–7224, October 1, 2001] Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines Henriette Gourdeau,1,2 Marilyn L. Clarke,1 France Ouellet, Delores Mowles, Milada Selner, Annie Richard, Nola Lee, John R. Mackey, James D. Young,3 Jacques Jolivet, Ronald G. Lafrenie`re, and Carol E. Cass4 Shire BioChem Inc., Laval, Que´bec, H7V 4A7 Canada [H. G., F. O., A. R., N. L., J. J., R. G. L.]; Departments of Oncology [M. L. C., J. R. M., C. E. C.] and Physiology [J. D. Y.], University of Alberta, Alberta T6G 1Z2 Canada; and Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 Canada [M. L. C., D. M., M. S., J. R. M., C. E. C.] ABSTRACT oxycytidine analogues such as gemcitabine (2Ј,2Ј-difluorodeoxycyti- dine; dFdC) and cytarabine (1-␤-D-arabinofuranosylcytosine; araC), -Troxacitabine (Troxatyl; BCH-4556; (-)-2؅-deoxy-3؅-oxacytidine), a de which are in the ␤-D configuration, troxacitabine has a nonnatural ␤-L oxycytidine analogue with an unusual dioxolane structure and nonnatural configuration. Troxacitabine, which shares the same intracellular ac- L-configuration, has potent antitumor activity in animal models and is in clinical trials against human malignancies. The current work was under- tivation pathway as gemcitabine and cytarabine, undergoes a series of taken to identify potential biochemical mechanisms of resistance to trox- phosphorylation reactions through a first rate-limiting step catalyzed 5 acitabine and to determine whether there are differences in resistance by dCK (EC 2.7.1.74) to form the active triphosphate nucleotide.
    [Show full text]